<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468231</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-20180309</org_study_id>
    <nct_id>NCT03468231</nct_id>
  </id_info>
  <brief_title>HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC</brief_title>
  <official_title>Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiping Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Twelfth People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of University of South China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
      chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of
      oxaliplatin alone in patients with hepatocellular carcinoma (HCC) with major portal venous
      tumor thrombus (PVTT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is the most widely used palliative treatment for hepatocellular carcinoma (HCC)
      patients with portal venous tumor thrombus (PVTT). Our previous prospective study revealed
      that sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin
      plus fluorouracil/leucovorin confer a survival benefit to HCC with major PVTT. However, HAIC
      of fluorouracil is not such for advanced HCC. Whether HAIC of oxaliplatin is as effective as
      HAIC of oxaliplatin plus fluorouracil/leucovorin is controversial. Thus, the investigators
      carried out this prospective randomized control study to find out it.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">March 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>In the OXA group, saline replace the fluorouracil and leucovorin solution and patients are treated the same time as the FOLFOX group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 months</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>10 months</time_frame>
    <description>Progress free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of adverse events. Postoperative adverse events were graded based on CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of of Patients developed Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of of patients who developed adverse event. Postoperative adverse events were graded based on CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>10 months</time_frame>
    <description>overall response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib plus HAIC of FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenbi plus HAIC of OXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Oral Sorafenib, 400mg, Bid</description>
    <arm_group_label>Sorafenib plus HAIC of FOLFOX</arm_group_label>
    <arm_group_label>Sorafenbi plus HAIC of OXA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAIC of FOLFOX</intervention_name>
    <description>administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries</description>
    <arm_group_label>Sorafenib plus HAIC of FOLFOX</arm_group_label>
    <other_name>Oxaliplatin , fluorouracil, and leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAIC of OXA</intervention_name>
    <description>administration of Oxaliplatin via the tumor feeding arteries</description>
    <arm_group_label>Sorafenbi plus HAIC of OXA</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
        Association for the Study of the Liver (EASL)

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria.

          -  diagnosed with major or main portal vein invasion (Vp3 or Vp4)

          -  KPS≥70；

          -  with no previous treatment

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  The following laboratory parameters:

          -  Platelet count ≥ 75,000/µL

          -  Hemoglobin ≥ 8.5 g/dL

          -  Total bilirubin ≤ 30mmol/L

          -  Serum albumin ≥ 30 g/L

          -  ASL and AST ≤ 5 x upper limit of normal

          -  Serum creatinine ≤ 1.5 x upper limit of normal

          -  INR ≤ 1.5 or PT/APTT within normal limits

          -  Absolute neutrophil count (ANC) &gt;1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Hepatobiliary Oncology of Sun Yat-sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi, MD</last_name>
    <phone>(8620)-87343938</phone>
    <email>shiming@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RongPing Guo, MD</last_name>
    <phone>(8620)-87342266</phone>
    <email>guorp@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523059</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wusheng Yu, MD</last_name>
      <phone>13827285010</phone>
      <email>yuwusheng1998@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD</last_name>
      <phone>86-2087343115</phone>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guosheng Tan, MD</last_name>
      <phone>13725254145</phone>
      <email>tgs1976@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Twelfth People 's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanmin Zhou, MD</last_name>
      <phone>15521278919</phone>
      <email>13430288977@139.com</email>
    </contact>
    <investigator>
      <last_name>Jinghua Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiping Central Hospital</name>
      <address>
        <city>Kaiping</city>
        <state>Guangdong</state>
        <zip>529300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shijie Zhang, MD</last_name>
      <phone>13717287622</phone>
      <email>Shijie_9262511@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of University Of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Wu, MD</last_name>
      <phone>13975486015</phone>
      <email>wxp19730806@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zheng, MD</last_name>
      <phone>13649265446</phone>
      <email>183421344@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Oxaliplatin plus Fluorouracil/Leucovorin</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

